Literature DB >> 33922858

Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis.

Elisa Baratella1, Barbara Ruaro2, Fabiola Giudici3,4, Barbara Wade5, Mario Santagiuliana2, Francesco Salton2, Paola Confalonieri2, Michele Simbolo6, Aldo Scarpa6, Saverio Tollot1, Cristina Marrocchio1, Maria Assunta Cova1, Marco Confalonieri2.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease (ILD). This prospective observational study aimed at the evaluation of any correlation between genetic variants associated with IPF susceptibility and high-resolution computed tomography (HRCT) patterns. It also aimed at evidencing any differences in the HRTC pattern between the familial and sporadic form at diagnosis and after two years.
METHODS: A total of 65 IPF patients (mean age at diagnosis 65 ± 10) were enrolled after having given written informed consent. HRCT and genetic evaluations were performed.
RESULTS: A total of 19 familial (mean age 62 ± 15) and 46 sporadic (mean age 70 ± 9) IPF patients were enrolled. A statistically significant difference was evidenced in the HRTC pattern at diagnosis between the two groups. Sporadic IPF patients had a predominantly usual interstitial pneumonia (UIP) pattern compared with those patients with familial IPF (60.0% vs. 21.1%, respectively). Moreover, familial IPF patients had more alternative diagnoses than those with sporadic IPF (31.6% vs. 2.2%, respectively). Furthermore, there was a slight increase in the typical UIP pattern in the familial IPF group at two years from diagnosis.
CONCLUSIONS: Genetic factors play a pivotal role in the risk of developing IPF. However, further studies are required to clarify how these genetic factors may guide clinical treatment decisions.

Entities:  

Keywords:  familial idiopathic pulmonary fibrosis; high-resolution computed tomography (HRCT); idiopathic pulmonary fibrosis; interstitial lung disease

Year:  2021        PMID: 33922858     DOI: 10.3390/diagnostics11050762

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  44 in total

1.  Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation.

Authors:  Vincent Cottin; Philippe Reix; Chahéra Khouatra; Françoise Thivolet-Béjui; Delphine Feldmann; Jean-François Cordier
Journal:  Thorax       Date:  2011-01-19       Impact factor: 9.139

Review 2.  Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Authors:  David A Lynch; Nicola Sverzellati; William D Travis; Kevin K Brown; Thomas V Colby; Jeffrey R Galvin; Jonathan G Goldin; David M Hansell; Yoshikazu Inoue; Takeshi Johkoh; Andrew G Nicholson; Shandra L Knight; Suhail Raoof; Luca Richeldi; Christopher J Ryerson; Jay H Ryu; Athol U Wells
Journal:  Lancet Respir Med       Date:  2017-11-15       Impact factor: 30.700

3.  Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred.

Authors:  S Ono; T Tanaka; M Ishida; A Kinoshita; J Fukuoka; M Takaki; N Sakamoto; Y Ishimatsu; S Kohno; T Hayashi; M Senba; M Yasunami; Y Kubo; L M Yoshida; H Kubo; K Ariyoshi; K Yoshiura; K Morimoto
Journal:  Eur Respir J       Date:  2011-08-04       Impact factor: 16.671

4.  Rare variants in RTEL1 are associated with familial interstitial pneumonia.

Authors:  Joy D Cogan; Jonathan A Kropski; Min Zhao; Daphne B Mitchell; Lynette Rives; Cheryl Markin; Errine T Garnett; Keri H Montgomery; Wendi R Mason; David F McKean; Julia Powers; Elissa Murphy; Lana M Olson; Leena Choi; Dong-Sheng Cheng; Elizabeth Marchani Blue; Lisa R Young; Lisa H Lancaster; Mark P Steele; Kevin K Brown; Marvin I Schwarz; Tasha E Fingerlin; David A Schwartz; William E Lawson; James E Loyd; Zhongming Zhao; John A Phillips; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2015-03-15       Impact factor: 21.405

5.  Telomerase mutations in families with idiopathic pulmonary fibrosis.

Authors:  Mary Y Armanios; Julian J-L Chen; Joy D Cogan; Jonathan K Alder; Roxann G Ingersoll; Cheryl Markin; William E Lawson; Mingyi Xie; Irma Vulto; John A Phillips; Peter M Lansdorp; Carol W Greider; James E Loyd
Journal:  N Engl J Med       Date:  2007-03-29       Impact factor: 91.245

6.  MUC5B promoter polymorphism and interstitial lung abnormalities.

Authors:  Gary M Hunninghake; Hiroto Hatabu; Yuka Okajima; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Tetsuro Araki; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; Elissa Murphy; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha E Fingerlin; Ivan O Rosas; George R Washko; George T O'Connor; David A Schwartz
Journal:  N Engl J Med       Date:  2013-05-21       Impact factor: 91.245

7.  Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift.

Authors:  Pablo Cingolani; Viral M Patel; Melissa Coon; Tung Nguyen; Susan J Land; Douglas M Ruden; Xiangyi Lu
Journal:  Front Genet       Date:  2012-03-15       Impact factor: 4.599

Review 8.  Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; William E Lawson; Lisa R Young; Timothy S Blackwell
Journal:  Dis Model Mech       Date:  2013-01       Impact factor: 5.758

9.  DNA qualification workflow for next generation sequencing of histopathological samples.

Authors:  Michele Simbolo; Marisa Gottardi; Vincenzo Corbo; Matteo Fassan; Andrea Mafficini; Giorgio Malpeli; Rita T Lawlor; Aldo Scarpa
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  Epithelial-Mesenchymal Transition: A Major Pathogenic Driver in Idiopathic Pulmonary Fibrosis?

Authors:  Francesco Salton; Barbara Ruaro; Paola Confalonieri; Marco Confalonieri
Journal:  Medicina (Kaunas)       Date:  2020-11-13       Impact factor: 2.430

View more
  11 in total

1.  Catalpol Attenuates Pulmonary Fibrosis by Inhibiting Ang II/AT1 and TGF-β/Smad-Mediated Epithelial Mesenchymal Transition.

Authors:  Qun Yu; Dewei Zhu; Yang Zou; Kai Wang; Peili Rao; Yunhui Shen
Journal:  Front Med (Lausanne)       Date:  2022-05-24

2.  Changes in Thoracic Cavity Volume After Bilateral Lung Transplantation.

Authors:  Woo Sik Yu; Chul Hwan Park; Hyo Chae Paik; Jin Gu Lee; Seulgi You; Jaeyong Shin; Junho Jung; Seokjin Haam
Journal:  Front Med (Lausanne)       Date:  2022-05-26

3.  Glutamine Metabolism Is Required for Alveolar Regeneration during Lung Injury.

Authors:  Sisi Wang; Xue Li; Qingwen Ma; Qi Wang; Junping Wu; Hongzhi Yu; Kuan Li; Yu Li; Jianhai Wang; Qiuyang Zhang; Youwei Wang; Qi Wu; Huaiyong Chen
Journal:  Biomolecules       Date:  2022-05-22

4.  Discrimination between NSIP- and IPF-Derived Fibroblasts Based on Multi-Parameter Characterization of Their Growth, Morphology and Physic-Chemical Properties.

Authors:  Barbara Orzechowska; Kamil Awsiuk; Dawid Wnuk; Joanna Pabijan; Tomasz Stachura; Jerzy Soja; Krzysztof Sładek; Joanna Raczkowska
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 5.  Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Shengming Liu; Shanrui Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

6.  Zoledronic Acid Targeting of the Mevalonate Pathway Causes Reduced Cell Recruitment and Attenuates Pulmonary Fibrosis.

Authors:  Lloyd Tanner; Jesper Bergwik; Andrew B Single; Ravi K V Bhongir; Jonas S Erjefält; Arne Egesten
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

7.  Chronic Thromboembolic Pulmonary Hypertension: An Observational Study.

Authors:  Barbara Ruaro; Paola Confalonieri; Gaetano Caforio; Elisa Baratella; Riccardo Pozzan; Stefano Tavano; Chiara Bozzi; Selene Lerda; Pietro Geri; Marco Biolo; Maurizio Cortale; Marco Confalonieri; Francesco Salton
Journal:  Medicina (Kaunas)       Date:  2022-08-13       Impact factor: 2.948

Review 8.  Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?

Authors:  Barbara Ruaro; Riccardo Pozzan; Paola Confalonieri; Stefano Tavano; Michael Hughes; Marco Matucci Cerinic; Elisa Baratella; Elisabetta Zanatta; Selene Lerda; Pietro Geri; Marco Confalonieri; Francesco Salton
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-22

Review 9.  High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?

Authors:  Barbara Ruaro; Elisa Baratella; Paola Confalonieri; Marco Confalonieri; Fabio Giuseppe Vassallo; Barbara Wade; Pietro Geri; Riccardo Pozzan; Gaetano Caforio; Cristina Marrocchio; Maria Assunta Cova; Francesco Salton
Journal:  Diagnostics (Basel)       Date:  2021-12-07

Review 10.  An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Francesco Salton; Elisa Baratella; Paola Confalonieri; Pietro Geri; Riccardo Pozzan; Chiara Torregiani; Roberta Bulla; Marco Confalonieri; Marco Matucci-Cerinic; Michael Hughes
Journal:  Diagnostics (Basel)       Date:  2022-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.